Kin Fai Chan

Title: Innovations of Kin Fai Chan in Cancer Research

Introduction

Kin Fai Chan is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of cancer research, particularly in developing compounds that modulate multidrug resistance (MDR) in cancer cells. With a total of 2 patents, his work is recognized for its potential impact on cancer treatment.

Latest Patents

One of Kin Fai Chan's latest patents focuses on alkyne-, azide-, and triazole-containing flavonoids as modulators for multidrug resistance in cancers. This innovative research led to the construction of a triazole bridged flavonoid dimer compound library through the cycloaddition reaction of flavonoid-containing azides and alkynes. The resulting compounds were screened for their ability to reverse MDR in various overexpressed cell lines, including P-glycoprotein (P-gp), MRP1, and BCRP. The findings revealed promising MDR reversal activity, with compounds demonstrating varying selectivity for different transporters. Notably, some compounds exhibited EC50 values at or below 10 nM in BCRP-overexpressed cell lines, indicating their potential as selective inhibitors.

Career Highlights

Kin Fai Chan has worked with prestigious institutions such as The Hong Kong Polytechnic University and McGill University. His research has contributed to the understanding of how certain compounds can enhance the effectiveness of chemotherapy by overcoming drug resistance in cancer cells.

Collaborations

Throughout his career, Kin Fai Chan has collaborated with notable colleagues, including Larry Ming Cheung Chow and Tak Hang Chan. These collaborations have further enriched his research and innovation in the field of cancer treatment.

Conclusion

Kin Fai Chan's work in developing flavonoid-based compounds represents a significant advancement in the fight against cancer. His innovative approach to addressing multidrug resistance holds promise for improving treatment outcomes for patients.